PMID- 36995894
OWN - NLM
STAT- MEDLINE
DCOM- 20230503
LR  - 20230503
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
VI  - 188
IP  - 4
DP  - 2023 Apr 5
TI  - In-depth proteomic signature of parathyroid carcinoma.
PG  - 385-394
LID - 10.1093/ejendo/lvad046 [doi]
AB  - OBJECTIVE: Diagnosing parathyroid carcinoma (PC) is complicated and controversial 
      that early diagnosis and intervention are often difficult. Therefore, we aimed to 
      elucidate the protein signatures of PC through quantitative proteomic analyses to 
      aid in the early and accurate diagnosis of PC. DESIGN: We conducted a 
      retrospective cohort study. METHODS: We performed liquid chromatography with 
      tandem mass spectrometry using formalin-fixed paraffin-embedded samples. For the 
      analyses, 23 PC and 15 parathyroid adenoma (PA) tissues were collected from 6 
      tertiary hospitals in South Korea. RESULTS: The mean age of the patients was 52 
      years, and 63% were women. Proteomic expression profiling revealed 304 
      differentially expressed proteins (DEPs) with a cut-off of P < .05 and fold 
      change >1.5. Among DEPs, we identified a set of 5 proteins that can discriminate 
      PC from PA: carbonic anhydrase 4 (CA4), alpha/beta hydrolase domain-containing 
      protein 14B (ABHD14B), laminin subunit beta-2 (LAMB2), CD44 antigen (CD44), and 
      alpha-1-acid glycoprotein 1 (ORM1) that exhibited the highest area under the 
      curve of 0.991 in neural network model. The nuclear percentage of CA4 and LAMB2 
      in immunohistochemistry was significantly lower in PC tissue than in the PA (CA4: 
      2.77 +/- 1.96%, 26.2 +/- 3.45%, P < .001; LAMB2: 6.86 +/- 3.46%, 38.54 +/- 4.13%, P < 
      .001). The most enriched canonical pathways in PC included glycoprotein-6 
      signaling and mammalian target of rapamycin (mTOR). CONCLUSIONS: We identified 
      key proteins differentially expressed between PC and PA using proteomic analyses 
      of parathyroid neoplasms. These findings may help to diagnose PC accurately and 
      elucidate potential therapeutic targets.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of (ESE) 
      European Society of Endocrinology. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - Kong, Sung Hye
AU  - Kong SH
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, South Korea.
FAU - Lee, Joon-Hyop
AU  - Lee JH
AD  - Department of Surgery, Gachon University Gil Medical Center, Incheon, South 
      Korea.
FAU - Bae, Jeong Mo
AU  - Bae JM
AD  - Department of Pathology, Seoul National University Hospital, Seoul, South Korea.
FAU - Hong, Namki
AU  - Hong N
AUID- ORCID: 0000-0002-8246-1956
AD  - Department of Internal Medicine, Severance Hospital, Seoul, South Korea.
FAU - Kim, Hyeyoon
AU  - Kim H
AD  - Proteomics Core Facility, Biomedical Research Institute, Seoul National 
      University Hospital, Seoul, South Korea.
FAU - Park, So Young
AU  - Park SY
AUID- ORCID: 0000-0002-4820-9415
AD  - Department of Endocrinology and Metabolism, College of Medicine, Kyung Hee 
      University, Seoul, South Korea.
FAU - Choi, Yong Jun
AU  - Choi YJ
AD  - Department of Endocrinology and Metabolism, Ajou University School of Medicine, 
      Suwon, South Korea.
FAU - Lee, Sihoon
AU  - Lee S
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Gachon 
      University Gil Medical Center, Incheon, South Korea.
FAU - Rhee, Yumie
AU  - Rhee Y
AUID- ORCID: 0000-0003-4227-5638
AD  - Department of Internal Medicine, Severance Hospital, Seoul, South Korea.
FAU - Kim, Sang Wan
AU  - Kim SW
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, South Korea.
AD  - Department of Internal Medicine, Seoul National University Boramae Medical 
      Center, Seoul, South Korea.
FAU - Han, Dohyun
AU  - Han D
AD  - Proteomics Core Facility, Biomedical Research Institute, Seoul National 
      University Hospital, Seoul, South Korea.
AD  - Transdisciplinary Department of Medicine & Advanced Technology, Seoul National 
      University Hospital, Seoul, South Korea.
FAU - Kim, Jung Hee
AU  - Kim JH
AUID- ORCID: 0000-0003-1932-0234
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, South Korea.
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul, South 
      Korea.
FAU - Shin, Chan Soo
AU  - Shin CS
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, South Korea.
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul, South 
      Korea.
LA  - eng
GR  - Korean Endocrine Society/
PT  - Journal Article
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
SB  - IM
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - Male
MH  - *Parathyroid Neoplasms/metabolism
MH  - Retrospective Studies
MH  - Proteomics
MH  - Republic of Korea
OTO - NOTNLM
OT  - parathyroid
OT  - parathyroid adenoma
OT  - parathyroid carcinoma
OT  - proteomics
COIS- Conflicts of interest: All authors have nothing to declare.
EDAT- 2023/03/31 06:00
MHDA- 2023/05/03 06:42
CRDT- 2023/03/30 12:15
PHST- 2022/12/13 00:00 [received]
PHST- 2023/03/05 00:00 [revised]
PHST- 2023/03/28 00:00 [accepted]
PHST- 2023/05/03 06:42 [medline]
PHST- 2023/03/31 06:00 [pubmed]
PHST- 2023/03/30 12:15 [entrez]
AID - 7095603 [pii]
AID - 10.1093/ejendo/lvad046 [doi]
PST - ppublish
SO  - Eur J Endocrinol. 2023 Apr 5;188(4):385-394. doi: 10.1093/ejendo/lvad046.